| human |
TDLo |
intravenous |
5mg/kg/14D-C (5mg/kg) |
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
GASTROINTESTINAL: NAUSEA OR VOMITING
GASTROINTESTINAL: OTHER CHANGES |
Cancer Vol. 34, Pg. 972, 1974. |
| mouse |
LD50 |
intraperitoneal |
650mg/kg (650mg/kg) |
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
GASTROINTESTINAL: NAUSEA OR VOMITING |
Proceedings of the Society for Experimental Biology and Medicine. Vol. 97, Pg. 470, 1958. |
| mouse |
LD50 |
oral |
147mg/kg (147mg/kg) |
? |
Progress Report for Contract No. NIH-NCI-E-C-72-3252, Submitted to the National Cancer Institute by Litton Bionetics, Inc. Vol. NCI-E-C-72-3252, Pg. 1973, |
| mouse |
LD50 |
unreported |
550mg/kg (550mg/kg) |
? |
Cancer Research. Vol. 46, Pg. 2703, 1986. |
| rat |
LD50 |
intraperitoneal |
1600mg/kg (1600mg/kg) |
? |
Clinical Proceedings of the Children's Hospital of the District of Columbia. Vol. 18, Pg. 307, 1962. |
| rat |
LD50 |
oral |
215mg/kg (215mg/kg) |
? |
Progress Report for Contract No. NIH-NCI-E-C-72-3252, Submitted to the National Cancer Institute by Litton Bionetics, Inc. Vol. NCI-E-C-72-3252, Pg. 1973, |
| women |
TDLo |
parenteral |
173mg/kg/82W- (173mg/kg) |
SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" |
Journal of the National Medical Association. Vol. 79, Pg. 669, 1987. |
